Past Press Releases - Affimed Therapeutics AG

June 5, 2008
Affimed appoints Chief Business Officer
Affimed Therapeutics AG, a biopharmaceutical company focused on the development of antibody therapeutics, today announced that it has appointed Volker Lang, Ph.D., as its Chief Business Officer. More

May 13, 2008
Affimed validates antibody target for cancer metastasis
Affimed Therapeutics AG, a biopharmaceutical company focused on the development of antibody therapeutics, announced today that a collaboration with Dr. Stefan Weiss at the Institute of Biochemistry of the Ludwig Maximilian University in Munich has strongly validated a target for cancer metastases amenable to the development of antibodies or other therapeutic interventions. More

April 4, 2007
Affimed Closes € 25 MM (US $ 32 MM) Series B financing
HEIDELBERG, Germany - April 4, 2007 - Affimed Therapeutics, AG, a leading developer of next generation antibody therapeutics, announced today the closing of a € 25 million (US $ 32 million) Series B financing to enable the Company to fund the clinical development of its lead products.
More

October 2, 2006
XOMA and Affimed Sign Antibody Cross-License and Collaboration Agreement
XOMA Ltd. and Affimed Therapeutics AG have signed a cross-license and collaboration agreement for antibody-related technologies. More